THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
|
|
- Nathaniel Lynch
- 6 years ago
- Views:
Transcription
1 THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
2 Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology Board of Pfizer Educational Grant : Servier Laboratories
3 Hansson GK. N Engl J Med 2005;352:
4 Hansson GK. N Engl J Med 2005;352:
5 Hansson GK. N Engl J Med 2005;352:
6 Hansson GK. N Engl J Med 2005;352:
7
8 Atherosclerosis in Inflammatory disorders Skaggs, B. J. et al. (2012) Accelerated atherosclerosis in patients with SLE mechanisms and management Nat. Rev. Rheumatol. doi: /nrrheum
9
10 Figure 1. In RA, primary site of inflammation is synovial tissue, from which cytokines can be released into systemic circulation.
11 .
12 Table 1 Associations between chronic inflammatory diseases and vascular damage Kaplan MJ (2009) Management of cardiovascular disease risk in chronic inflammatory disorders Nat Rev Rheumatol doi: /nrrheum
13 Rheumatoid Arthritis Prevalence: 1 % Increased mortality from CVD MI 2x commoner in with RA as compared to controls Traditional risk factors do not influence CVS mortality in RA pts. RA pts have a higher prevalence of diastolic dysfunction Increased mortality in RA pts with MI as compared to controls
14 High incidence of silent ischaemia RA specific factors play a role Extent of atherosclerosis proportional to disease activity Male and advanced age of onset poor prognosis
15
16
17
18
19 SLE Autoimmune disease affecting predominantly women of child-bearing age High rate of premature CVD CVD most common cause of death in pts with SLE Framingham risk factors are less important predictors of CVS events in pts with active SLE > 40% of pts with SLE have asymptomatic myocardial perfusion abnormalities High incidence of increased LV mass
20 Risk Factors for Atherosclerosis and Risk Factors Related to Systemic Lupus Erythematosus (SLE). Hahn BH. N Engl J Med 2003;349:
21 Figure 2 Continuum of SLE-specific and traditional risk factors for CVD Skaggs, B. J. et al. (2012) Accelerated atherosclerosis in patients with SLE mechanisms and management Nat. Rev. Rheumatol. doi: /nrrheum
22 Antiphospholipid Syndrome Poor correlation between APLS and premature atherosclerosis SLE with anti β 2 G1 antibodies have increased incidence of MI
23 Psoriasis and PsA Chronic inflammatory conditions Increased prevalence and severity of CVS in these pts
24 Systemic Sclerosis Myocardial perfusion injury- well documented in PSS Patent epicardial vessels and normal intramural coronary vessels Oral nifedipine associated with improvement in myocardial perfusion
25 Ankylosing Spondylitis Mortality fold greater in pts with AS as compared to general population
26 SjÖgren s Syndrome Endothelial dysfunction well documented in Sjogren s Syndrome Immune dysregulation Higher incidence in pts with Anti-Ro antibodies and leucopenia Unclear if Sjogren s Syndrome is an independent risk factor for premature CVD
27 Mechanisms of premature CVD TRADITIONAL AS WELL AS NON TRADITIONAL RISK FACTORS
28 Non-traditional risk factors Striking similarities noted in the inflammatory and immunologic reactions of Atherosclerosis and RA
29 Reasons for the development of CVD in RA complex Several mechanisms
30 proinfl cytokines Abn vasc repair genes Premature CVD
31 Cytotoxic T cells Antibodies to endothelial cells Steroid use Premature CVD
32 Increased levels of Pro-inflammatory cytokines TNF α IL-6 IL-17 CRP
33 Abnormal Vascular Repair circulating EPC s Quantitative and qualitative defect in EPC s in RA/SLE/PSS Imbalance between vascular damage and repair Leads to endothelial dysfunction SLE- increased apoptosis of endothelial cells
34 Atherosclerosis in Inflammatory disorders Skaggs, B. J. et al. (2012) Accelerated atherosclerosis in patients with SLE mechanisms and management Nat. Rev. Rheumatol. doi: /nrrheum
35 Genetic Polymorphism TNF receptor Type II Genetic polymorphism of PAI I Coagulation factor XIII subunit A
36 Cytotoxic T cells ed levels of CD4 + CD28 - in pts with RA These cells cause endothelial cell cytotoxicity
37 Autoantibodies To endothelial cells components Their precise role as yet unclear
38 Corticosteroids Inconsistent results from clinical trials HYPERTENSION INSULIN RESISTANCE Steroids induce LIPID Abnormalities CVD OBESITY
39 Steroids in Chronic Inflammatory Dses Exact role of steroids in the development of CVD in chronic inflammatory conditions is yet to be defined
40 Traditional risk factors Smoking Systemic Hypertension Dyslipidaemias Microalbuminuria Insulin resistance Hyperhomocysteinaemia
41 Risk Assessment and Prevention Preventive strategies to start soon after diagnosis Awareness Guidelines lacking Unanswered questions???
42 Decreasing Traditional Risk Factors Kaplan MJ (2009) Management of cardiovascular disease risk in chronic inflammatory disorders Nat Rev Rheumatol doi: /nrrheum
43 Decreasing Disease specific risk Factors Paracetamol NSAIDS : COX II vs NS NSAIDS Aggressive treatment of underlying condition Hydroxychloroquine in SLE Corticosteroids Methotrexate Biologics
44 Summary: Patients with systemic inflammatory diseases are at significantly increased risk of cardiovascular events, which contribute to the high morbidity and mortality associated with these diseases
45 Evidence suggests that rheumatoid arthritis and systemic lupus erythematosus are independent risk factors for the development of premature cardiovascular disease (CVD
46 As factors promoting premature CVD-associated mortality might be present early in the natural history of inflammatory disease, preventive strategies to decrease cardiovascular risk should start shortly after diagnosis
47 Specific guidelines need to be developed that address the management of cardiovascular risk factors in rheumatoid arthritis, systemic lupus erythematosus and potentially other inflammatory conditions
48 Recent evidence suggests that optimal treatment of inflammatory disorders could result in improvements in vascular function and lead to decreases in the risk of CVD
49
50
51
52
53
54
55 References: 1. Fishbein, M. C. The vulnerable andunstable atherosclerotic plaque. Cardiovasc.Pathol. [doi: /j.carpath ](2008). 2. schillinger, M. et al. inflammation and carotidartery risk for atherosclerosis study(icaras). Circulation 111, (2005). 3. ridker, P. M. et al. inflammation, aspirin, and therisk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, (1997). 4. ridker, P. M. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, (2000). 5. ross, r. Atherosclerosis is an inflammatory disease. Am. Heart J. 138, s419 s420 (1999). 6. Libby, P. inflammation in atherosclerosis. Nature 420, (2002). 7. Manzi, s. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J.Epidemiol. 145, (1997). 8. Maradit-Kremers, H. et al. increased unrecognized coronary heart disease andsudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheu52, (2005).
56 9. solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, (2003). 10. Avina-Zubieta, J. A. et al. risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59, (2008). 11. solomon, D. H. et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 50, (2004). 12. sodergren, A. et al. increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann. Rheum. Dis. 66, (2007). 13. Goodson, N. J. et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, (2002). 14. Bergholm, r. et al. impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 22, (2002). 15. wallberg-jonsson, s. et al. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern sweden. J. Rheumatol. 24, (1997). 16. Davis, J. M. et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 58, (2008).
57 Thank You!
Rheumatoid Arthritis: An update for non rheumatologists
Rheumatoid Arthritis: An update for non rheumatologists Dimitrios Pappas, M.D., M.P.H. Assistant Professor of Medicine Columbia University, College of Physicians & Surgeons Director of Rheumatology Athens
More informationLupus as a risk factor for cardiovascular disease
Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo
More informationCIC Edizioni Internazionali. Cardio-metabolic comorbidities in rheumatoid arthritis and SLE. Review. 120 Clinical Dermatology 2013; 1 (2):
Review Cardio-metabolic comorbidities in rheumatoid arthritis and SLE Andrea Doria Division of Rheumatology University of Padua, Italy Address for correspondence: Division of Rheumatology University of
More informationLupus and the heart. Lupus Foundation of America
Lupus and the heart Lupus Foundation of America Teleconference FEB 2015 Premature Atherosclerotic ti Cardiovascular Disease in Systemic Lupus Erythematosus Joan M. Von Feldt, MD, MSEd Professor of Medicine
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationA Study of Atherosclerosis in Systemic Vasculitis
Original Article A Study of Atherosclerosis in Systemic Vasculitis Silas Supragya Nelson, Sonjjay Pande, Avadhesh Pratap Singh Kushwah 3 Assistant Professor in the Department of Medicine, NSCB Medical
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationUNIVERSITY OF CALGARY. Development and Testing of Cardiovascular Quality Indicators for Rheumatoid Arthritis. Claire Ellen Hawkins Barber A THESIS
UNIVERSITY OF CALGARY Development and Testing of Cardiovascular Quality Indicators for Rheumatoid Arthritis by Claire Ellen Hawkins Barber A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL
More informationAutoimmune disorders: An emerging risk factor for CV disease
Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's
More informationHans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationSubclinical Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Supplement issue Subclinical Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus Jane E. Salmon, MD, a,b and Mary J. Roman, MD b a Mary Kirkland Center for Lupus Research, Hospital
More informationInflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.
More informationRheumatoid arthritis (RA) is the most common systemic
Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Daniel H. Solomon, MD, MPH; Elizabeth W. Karlson, MD; Eric B. Rimm, ScD; Carolyn C. Cannuscio, ScD; Lisa A. Mandl, MD, MPH; JoAnn
More informationKey words: antiphospholipid syndrome, trombosis, pathogenesis
26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationPrevalence of Abnormal Ankle Brachial Index in Iraqi Patients with Systemic Lupus Erythematosus
ANKLE THE IRAQI BRACHIAL POSTGRADUATE INDEX MEDICAL IN SYSTEMIC JOURNAL LUPUS ERYTHEMATOSUS Prevalence of Abnormal Ankle Brachial Index in Iraqi Patients with Systemic Lupus Erythematosus Ziad S. Al-Rawi*,
More informationSubodh Verma, MD PhD FRCSC
CIRT and CANTOS Targeting g Inflammation at in Atherosclerosis e s Subodh Verma, MD PhD FRCSC Cardiac Surgeon, St. Michael s Hospital Associate Professor, Surgery & Pharmacology Canada Research Chair in
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationLow grade inflammation and cardiovascular disease
Low grade inflammation and cardiovascular disease Konstantinos Aznaouridis, MD PhD 1 st Department of Cardiology Hippokration Hospital Athens Medical School Atherosclerosis Start from very young To Old
More informationAccelerated Atherosclerosis in Autoimmune Rheumatic Diseases Prof. Andrea Doria
Accelerated Atherosclerosis Andrea Doria Division of Rheumatology University of Padova 1 Endothelial Dysfunction Fatty-Streak Formation Endothelial Leukocyte Endothelial Leukocyte permeability migration
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationAssessment for Early Cardiovascular Risk in Pediatric Rheumatic Disease
Assessment for Early Cardiovascular Risk in Pediatric Rheumatic Disease by Pascal Norman Tyrrell A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationPsoriasis and the metabolic syndrome
Psoriasis and the metabolic syndrome MD, PhD James G. Krueger 1 Inflammation as a foundation of metabolic dysregulation and cardiovascular disease risk Diseases of systemic immune activation and inflammation,
More informationMetabolic syndrome in patients with autoimmune inflammatory rheumatisms.
Biomedical Research 2018; 29 (11): 2416-2420 ISSN 0970-938X www.biomedres.info Metabolic syndrome in patients with autoimmune inflammatory Elena Amaricai *, Liliana Catan, Daniel Popa, Mihai Dragoi, Dan
More informationAccelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions
Review International Journal of Clinical Rheumatology ith ns Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions Atherosclerosis is a complex inflammatory disease
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationSubclinical inflammation and peripheral artery disease. Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY
Subclinical inflammation and peripheral artery disease Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY ESC Congress 2010 Conflict of interest Research grants:sanofi-aventis,
More informationNot only...but also : factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus
Rheumatology 2005;44:1492 1502 Advance Access publication 18 October 2005 Review doi:10.1093/rheumatology/kei142 Michael Mason Prize Essay Not only...but also : factors that contribute to accelerated atherosclerosis
More informationRisk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study
Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j895 (Published
More informationCARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS AT KENYATTA NATIONAL HOSPITAL
CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS AT KENYATTA NATIONAL HOSPITAL Kirui K Fredrick MBCHB,MMED KEMRI/WRP HIV PROGRAM KERICHO EPIDEMIOLOGY Rheumatoid arthritis (RA) is a disease
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationHeart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More information- Clinical Background, Motivation and my Experience at F2F meeting
Predicting randomized clinical trial results with realworld evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis - Clinical Background,
More informationNOVEL BIOMARKERS AS RISK FACTORS FOR CARDIOVASCULAR DISEASE
NOVEL BIOMARKERS AS RISK FACTORS FOR CARDIOVASCULAR DISEASE Amy Alman, PhD Assistant Professor of Epidemiology College of Public Health University of South Florida Causation is a concept central to epidemiology
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More informationDOTT. MATTEO NICOLA DARIO DI MINNO
UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II FACOLTÀ DI MEDICINA E CHIRURGIA DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA DOTTORATO DI RICERCA IN FISIOPATOLOGIA CLINICA E MEDICINA SPERIMENTALE DIRETTORE:
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationDISCLOSURE. Relevant relationships with commercial entities none. Potential for conflicts of interest within this presentation none
AUTOIMMUNITY DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and mitigate potential bias N/A MODULE
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationAbstract. Introduction. Daniel Li 1, Alex Meara 2, Brian LaMoreaux 2, Guy Brock 3, Wael Jarjour 2
Research Article http://www.alliedacademies.org/archives-of-general-internal-medicine/ ISSN : 2591-7951 Assessment of cardiovascular disease in rheumatoid arthritis patients. Daniel Li 1, Alex Meara 2,
More informationDemir Baykal,MD,FACC,FASE Diplomat ABCL,SCCT Gwinnett Consultants in Cardiology Medical Software,LLC
Demir Baykal,MD,FACC,FASE Diplomat ABCL,SCCT Gwinnett Consultants in Cardiology Medical Software,LLC 1950-1979 1980-1992 Gabriel, S. et al., Arthritis Rheum 1999;42:46-50. 1. Pericarditis 2. Myocarditis
More informationBacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation
Bacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation What is Plasmanex1? Plasmanex1 is a dietary supplement
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationREVIEWS. Cardiorheumatology: cardiac involvement in systemic rheumatic disease
Cardiorheumatology: cardiac involvement in systemic rheumatic disease Megha Prasad, Joerg Hermann, Sherine E. Gabriel, Cornelia M. Weyand, Sharon Mulvagh, Rekha Mankad, Jae K. Oh, Eric L. Matteson and
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationIS PRE-CLINICAL AUTOIMMUNITY BENIGN?
IS PRE-CLINICAL AUTOIMMUNITY BENIGN? Darcy S. Majka MD, MS Disclosures I have no significant financial or other relationship with the manufacturers of any product or services. Dr. Teodorescu (coauthor)
More informationIMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS.
1 IMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS. A NETWORK ORGANIZED BY THE EUROPEAN FEDERATION OF INTERNAL MEDICINE Coordination:
More informationPathogenesis of atherosclerosis in rheumatoid arthritis
Pathogenesis of atherosclerosis in rheumatoid arthritis JR Pambudi 1, H Isbagio 1 1 Division of Rheumatology, Department of Internal Medicine, University of Indonesia School of Medicine/ Cipto Mangunkusumo
More informationEpidemiology of Rheumatoid Arthritis: Rheumatoid Arthritis and Mortality
Curr Rheumatol Rep (2010) 12:379 385 DOI 10.1007/s11926-010-0117-y Epidemiology of Rheumatoid Arthritis: Rheumatoid Arthritis and Mortality Elena Myasoedova & John M. Davis III & Cynthia S. Crowson & Sherine
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationDemir Baykal,MD,FACC,FASE Diplomat ABCL,SCCT Gwinnett Consultants in Cardiology Medical Software,LLC
Demir Baykal,MD,FACC,FASE Diplomat ABCL,SCCT Gwinnett Consultants in Cardiology Medical Software,LLC 1950-1979 1980-1992 Gabriel, S. et al., Arthritis Rheum 1999;42:46-50. 1 1. Pericarditis 2. Myocarditis
More information(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
More informationIdentifying and Quantifying Dynamic Risk Factors for Coronary Artery Disease in Systemic Lupus Erythematosus
Identifying and Quantifying Dynamic Risk Factors for Coronary Artery Disease in Systemic Lupus Erythematosus by Mandana Nikpour A thesis submitted in conformity with the requirements for the degree of
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationThe Risk of Myocardial Infarction and Pharmacologic and Nonpharmacologic Myocardial Infarction Predictors in Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 58, No. 9, September 2008, pp 2612 2621 DOI 10.1002/art.23811 2008, American College of Rheumatology The Risk of Myocardial Infarction and Pharmacologic and Nonpharmacologic
More informationMechanisms of Autontibodies
Mechanisms of Autontibodies Production in Rheumatic Diseases Eisa Salehi PhD Tehran University of Medical Sciences Immunology Department Introduction Rheumatic diseases: Cause inflammation, swelling, and
More informationFigure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE
CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should
More informationACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust
ACP-BSG meeting 10.12.09 The liver in systemic inflammatory disorders Dr Adrian C Bateman Southampton University Hospitals NHS Trust Wide range of diseases General inflammatory disorders Connective tissue
More informationBerries and Cardiovascular Health
Berries and Cardiovascular Health Britt Burton-Freeman, PhD Institute for Food Safety and Health Illinois Institute of Technology bburton@iit.edu Berry Health Benefits Symposium Westlake Village CA, 2011
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationParadoxial Safety Signals from Biologics
Paradoxial Safety Signals from Biologics Christopher Ritchlin, MD, MPH Professor of Medicine Director, Translational Immunology Research Center University of Rochester Medical Center Rochester, NY Disclosures
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationUndifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
More informationMen and Lupus. Epidemiology Men s Health Issues. Question and answer period. Coronary artery disease Osteoporosis Prostate cancer Sexual health
Men and Lupus Joseph Shanahan, MD Assistant Consulting Professor in Medicine Duke University Medical Center Durham, North Carolina Shanahan Rheumatology & Immunotherapy Raleigh, North Carolina Men and
More informationThe Gender Divide Women, Men and Heart Disease February 2017
The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationClassic DMARD s, biologic drugs and cancer risk
Classic DMARD s, biologic drugs and cancer risk Prof. Dr. António M. F. Araújo Head of the Service of Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas de Abel Salazar Disclosure
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More information